Angiopoietin-1 and Vascular Endothelial Growth Factor Regulation of Leukocyte Adhesion to Endothelial Cells: Role of Nuclear Receptor-77
Overview
Authors
Affiliations
Objective: Vascular endothelial growth factor (VEGF) promotes leukocyte adhesion to endothelial cells (ECs). Angiopoietin-1 (Ang-1) inhibits this response. Nuclear receptor-77 (Nur77) is a proangiogenic nuclear receptor. In the present study, we assessed the influence of Ang-1 and VEGF on Nur77 expression in ECs, and evaluated its role in Ang-1/VEGF-mediated leukocyte adhesion.
Methods And Results: Expression of Nur77 was evaluated with real-time polymerase chain reaction and immunoblotting. Adhesion of leukocytes to ECs was monitored with inverted microscopy. Nur77 expression or activity was inhibited using adenoviruses expressing dominant-negative form of Nur77, retroviruses expressing Nur77 in the antisense direction, and small interfering RNA oligos. Both Ang-1 and VEGF induce Nur77 expression, by >5- and 30-fold, respectively. When combined, Ang-1 potentiates VEGF-induced Nur77 expression. Ang-1 induces Nur77 through the phosphoinositide 3-kinase and extracellular signal-regulated protein kinase 1/2 pathways. VEGF induces Nur77 expression through the protein kinase D/histone deacetylase 7/myocyte enhancer factor 2 and extracellular signal-regulated protein kinase 1/2 pathways. VEGF induces nuclear factor-kappaB transcription factor, vascular cell adhesion molecule-1, and E-selectin expressions, and promotes leukocyte adhesion to ECs. Ang-1 inhibits these responses. This inhibitory effect of Ang-1 disappears when Nur77 expression is disrupted, restoring the inductive effects of VEGF on adhesion molecule expression, and increased leukocyte adhesion to ECs.
Conclusions: Nur77 promotes anti-inflammatory effects of Ang-1, and functions as a negative feedback inhibitor of VEGF-induced EC activation.
Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy.
Carelock M, Master R, Kim M, Jin Z, Wang L, Maharjan C Life Med. 2025; 2(3):lnad019.
PMID: 39872303 PMC: 11749652. DOI: 10.1093/lifemedi/lnad019.
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L, Xiao Y, Luo Y, Master R, Mo J, Kim M J Exp Med. 2024; 221(3).
PMID: 38334978 PMC: 10857906. DOI: 10.1084/jem.20231519.
Wu Z, Bai Y, Qi Y, Chang C, Jiao Y, Bai Y Cell Death Discov. 2023; 9(1):10.
PMID: 36653355 PMC: 9849262. DOI: 10.1038/s41420-023-01308-1.
Li Y, Hu Q, Luoreng Z, Yang J, Wang X, Ma Y Animals (Basel). 2022; 12(11).
PMID: 35681895 PMC: 9179474. DOI: 10.3390/ani12111431.
Poto R, Loffredo S, Palestra F, Marone G, Patella V, Varricchi G Cells. 2022; 11(10).
PMID: 35626756 PMC: 9139415. DOI: 10.3390/cells11101720.